GeneDx Q2 FY26 GAAP net loss widens to $17.7 million; revenue rises 11% year over year to $114.4 million

Reuters2026/08/03 20:13

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

GeneDx posted 2Q26 revenue of USD 114.4 million, up 11% year over year; GAAP net loss widened to USD 17.7 million.
Adjusted net income was USD 0.4 million, swinging from an adjusted net loss in 1Q26; GAAP gross margin was 68%.
Exome and genome revenue rose to USD 100.3 million, up 17% year over year; related result volume climbed to 30,785, up 32%.
Cash, cash equivalents, marketable securities and restricted cash totaled USD 133.5 million at June 30, 2026; pro forma cash was about USD 188 million after a Blackstone deal.
Reaffirmed 2026 revenue outlook of USD 475 million to USD 490 million; guided 3Q26 revenue to USD 122 million to USD 124 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genedx Holdings Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260803559557) on August 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

GeneDx Q2 FY26 GAAP net loss widens to $17.7 million; revenue rises 11% year over year to $114.4 million

You may also like

Crypto prices